-
November 22,2022
Press Release
Announcement of Preliminary Results for the Phase III Clinical Trial of Functional Peptide SR-0379 [PDF file]
-
October 17,2022
Press Release
Notice of Business Transfer to Consolidated Subsidiary [PDF file]
-
September 14,2022
Information
Notice of participation in “the 2022 NEDO Silicon Valley Pitch Night”
-
August 18,2022
Press Release
Exercise of Option by MEDIPAL HOLDINGS CORPORATION [PDF file]
-
July 25,2022
Press Release
Notice of Completion of Subject Enrollment in Phase III Clinical Trial of Functional Peptide SR-0379 [PDF file]
-
June 6,2022
Press Release
Notice Concerning the Completion of Subject Enrollment for the Phase I/IIa Clinical Study of Antibody-Inducing Peptide FPP003 [PDF file]
-
April 1,2022
Press Release
Announcement of the start of joint research with Kumamoto University [PDF file]
-
January 20,2022
Press Release
Notice of Agreement between FunPep and EPS Innovative Medicine on Collaboration in China Business [PDF file]
-
August 19,2021
Press Release
Announcing the Start of Administration of Functional Peptide SR-0379 to Subjects in Phase III Clinical Trial [PDF file]
-
August 13,2021
Press Release
FunPep Signs Joint Research Agreement for a Next-generation Drug Formulation Technology for Antibody Inducing Peptides Using Microneedle Array Patch [PDF file]